MMRC Names MDS Pharma Services as Preferred CRO
Complete the form below to unlock access to ALL audio articles.
The Multiple Myeloma Research Consortium has announced that it has selected MDS Pharma Services to serve as its preferred Contract Research Organization.
In this role, MDS Pharma Services will manage and execute MMRC pre-clinical and clinical research efforts, including data management related to the tissue accrual into the MMRC Tissue Bank.
The MMRC will also recommend MDS Pharma Services to industry partners as additional protocols are brought through the Consortium.
"MDS Pharma Services offers a full spectrum of advanced scientific and technological expertise to significantly accelerate each step of the drug discovery and development pathways," said Nancy Sumberaz, President, the MMRC.
"We are proud to consider MDS Pharma Services a true partner in our efforts to bring new therapeutic options to patients as quickly as possible."
"MDS Pharma Services is honored to have been chosen by the MMRC and we are ready to bring our global capabilities and oncology expertise to bear on the effort to fight multiple myeloma," says Alan Morgan, Vice President and General Manager for Global Clinical Development, MDS Pharma Services.
